AVITA Medical Names Cary Vance as Chief Executive Officer

Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately.

GlobeNewsWire • Apr 30, 2026

AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO

RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL ® Spray-On Skin™ for the treatment of burn and trauma wounds VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration (“TGA”) and has been listed on New Zealand's Web Assisted Notification of Devices (“WAND”) database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment.

GlobeNewsWire • Apr 29, 2026

AVITA Medical to Announce First Quarter 2026 Financial Results

VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026.

GlobeNewsWire • Apr 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCEL

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical Inc. (“AVITA Medical” or the “Company”) (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • Apr 21, 2026

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

Seeking Alpha • Apr 17, 2026

AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association

Recognition highlights pioneering contributions to modern burn care including development of RECELL ® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA).

GlobeNewsWire • Apr 15, 2026

Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?

Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Apr 15, 2026

AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting

Cohealyx interim data show ~20-day reduction in time to graft vs benchmark, with strong investigator satisfaction and consistent performance across wounds.

GlobeNewsWire • Apr 14, 2026

AVITA Medical, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AVITA Medical, Inc. , (“ AVITA " or the "Company") ( NASDAQ : RCEL ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

GlobeNewsWire • Apr 13, 2026

AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data

AVITA Medical highlights new Cohealyx data and real-world evidence at upcoming ABA 2026, advancing wound healing and improving patient recovery outcomes

GlobeNewsWire • Apr 7, 2026